SUBSCRIBE
SUBSCRIBE
News   FDA

U.S. Clears GlaxoSmithKline Drug For Preventing Influenza

March 29, 2006 | 
1 min read
WASHINGTON (Reuters) - GlaxoSmithKline Plc's prescription flu treatment Relenza has won U.S. approval for preventing influenza in adults and children ages 5 and older, regulators said on Wednesday.

FDA Approvals
GlaxoSmithKline
MORE ON THIS TOPIC
Holds tickets in hand, isolated on white background. Vector flat. stock illustration
Regulatory
FDA Hands Out First Commissioner’s Priority Vouchers to Regeneron, Sanofi, Disc, Others
October 17, 2025
 · 
2 min read
 · 
Tristan Manalac
REGULATORY
Webinar: Shifting Risk | Biopharma in an Age of Deregulation
October 16, 2025
 · 
1 min read
 · 
BioSpace Insights
Human resource management and recruitment concept. Job rotation or staff turnover icon.
Government
FDA’s Orphan Drug Director Out Amid IRA Exemption Rollout
October 16, 2025
 · 
2 min read
 · 
Tristan Manalac
Washington, D.C., USA- January 13, 2020: FDA Sign at its headquarters in Washington DC. The Food and Drug Administration (FDA or USFDA) is a federal agency of the USA.
Gene therapy
FDA’s Second Platform Designation Goes to Krystal After Sarepta Withdrawal
October 15, 2025
 · 
2 min read
 · 
Tristan Manalac